Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases

... over linezolid in resistance acquisition by Staph aureus among data to be presented at infectious disease ... including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci ... and methicillin-resistant Staphylococcus aureus strains; A. Louie, C. Fregeau, W. Liu, H. Conde, ...

Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009

... bacteria, specifically Staphylococcus aureus and methicillin-resistant S. aureus (MRSA). About Rib-X Pharmaceuticals, Inc. ... active against methicillin-resistant S. aureus , multidrug-resistant Streptococcus pneumoniae ...

ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance

... to treat enterocolitis caused by Staphylococcus aureus , including methicillin-resistant strains In ... indicated use of Vancocin - Staphylococcus aureus GI infections - which occur in both the upper ... and enterocolitis caused by Staphylococcus aureus , including methicillin-resistant strains. Orally ...

Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin

... including its activity against Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) and quinolone-resistant Gram-positive ... bacteria, specifically Staphylococcus aureus and methicillin-resistant ....

Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome

... MRSA Methicillin-resistant Staphylococcus aureus (MRSA) is a type of bacteria that is resistant to ... and 89.4 million people are colonized with S. aureus annually, according to the Centers for Disease ... hospitalizations with a diagnosis of S. aureus infection occur annually in U.S. hospitals and, ...

Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA

... detection of Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA), (typically Methicillin-sensitive) in ... or methicillin-susceptible Staphylococcus aureus -- are done via slower culture testing methods. ...

Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections

... including methicillin-resistant Staphylococcus aureus (MRSA) REINACH, Switzerland, Oct. 26 ... including methicillin-resistant Staphylococcus aureus (MRSA). In addition, iclaprim was well-tolerated ... between treatment groups with Staphylococcus aureus (S. aureus) as the predominant pathogen isolated ...

Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection

... vaccine for the prevention of Staphylococcus aureus (S. aureus) infections. This randomized double ... on clinical data obtained so far." The S. aureus vaccine candidate is based on a conserved protein ... net sales. In Phase I clinical trials the S. aureus candidate vaccine was shown to be immunogenic and ...

Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections

... methicillin-resistant Staphylococcus aureus (MRSA) NEW YORK, June 19 /PRNewswire-FirstCall/ ... clinical cure rate was 93.1% in Staphylococcus aureus infections in the microbiologically ... against vancomycin-resistant Staphylococcus aureus (VRSA), ...

BD Announces FDA 510(k) Clearance of Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures

... Test to Simultaneously Identify Staphylococcus aureus and Methicillin-Resistant Staphylococcus aureus from Positive Blood Cultures SAN DIEGO, Jan. 2 ... (HAIs) -- Staphylococcus aureus (SA) and ...

Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals

... combat methicillin-resistant staphylococcus aureus (MRSA) infections that are responsible for an ... "Invasive Methicillin-Resistant Staphylococcus aureus Infections in the United States," The ... (2007). Methicillin resistant Staphylococcus aureus (MRSA) study results. ...

Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria

... examined clinical isolates of Staphylococcus aureus (n=5,008) and coagulase-negative staphylococci ... of streptococci. Bacterial isolates included S. aureus (n=35), coagulase-negative staphylococci ... rifampicin against methicillin-sensitive S. aureus (MSSA), a clinical isolate of ...

New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA

... due to PVL- positive methicillin-resistant S. aureus (MRSA). These new data were presented in two ... is a toxin that -- when found in S. aureus -- "lyses," or breaks open, white blood cells and ... with MRSA, PVL-positive MRSA, or PVL-positive S. aureus infections, cure rates consistently exceeded 90%. ...

BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery

... Test to Simultaneously Identify Staphylococcus aureus and Methicillin-Resistant Staphylococcus aureus from Nasal Specimens SAN DIEGO, Sept. 11 ... and simultaneous identification of Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus ...

Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections

... drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA). The study achieved its primary goals of establishing safety and ... potential for the rapid treatment of severe infections caused by Staph aureus , including MRSA, in both the community and the hospital," said Jeffrey ...

Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki

... that NXL103 was active against methicillin resistant Staphylococcus aureus (MRSA) and organisms responsible for lower respiratory tract infections, ... drug-resistant and non-drug-resistant strains of Staphylococcus aureus in infected macrophages, (Poster P 1025). The final poster shows that ...

CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals

... from an analysis of a multifaceted methicillin-resistant Staphylococcus aureus (MRSA) prevention program that employed positive deviance (PD), a novel ... dropped, the hospitals saw a decline in the proportion of Staphylococcus aureus infections caused by methicillin-resistant bacteria, signifying that ...

Blue Light Destroys Antibiotic-Resistant Staph Infection - Results Reported in Photomedicine and Laser Surgery Journal

... are susceptible to penicillin, while approximately 40%-50% of Staph aureus isolated have developed resistance to newer semisynthetic antibiotics ... study, "Blue 470-nm Light Kills Methicillin-Resistant Staphylococcus aureus (MRSA) in Vitro ," the authors exposed bacterial colonies of MRSA to ...

MicroPhage Successfully Completes Beta Trial for Rapid MRSA Test

... study evaluated MicroPhage's prototype assay to identify Staphylococcus aureus (staph) bacteria and determine methicillin resistance (MRSA) or ... for culture testing methods, and had an excellent detection rate for S. aureus bacteria of 93 percent while also determining methicillin resistance or ...

Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA

... of TR-701 in a Mouse Thigh Infection Model Against S. aureus ATCC 33591, a Methicillin-Resistant Isolate Monday, October 27th ... TR-700 Versus the Linezolid- and Methicillin-Resistant Staphylococcus aureus cfr Strain CM/05 -- F1-2066: Demonstration of TR-701 Efficacy in a ...

Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA

... gram-positive infections, including methicillin-resistant Staphylococcus aureus (MRSA). Preclinically, EDP-322 has demonstrated strong in vitro activity ... to the Centers for Disease Control and Prevention. Staphylococcus aureus is a bacterium that can live harmlessly on human skin and is found in the ...

Study Shows Use of AdvanDx's PNA FISH(TM) Test was Associated with an 82% Reduction in Intensive Care Unit Mortality Rates from Staphylococcus aureus Bloodstream Infections

... test was associated with an 82% reduction in mortality rates from S. aureus bloodstream infections in the intensive care unit (ICU), a 53% reduction ... with antibiotics. PNA FISH provides rapid, molecular identification of S. aureus and CoNS directly from positive blood cultures in hours instead of days. ...

Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)

... caused by pathogens such as CA-MRSA." About Staphylococcus aureus (MRSA) Methicillin-resistant Staphylococcus aureus (MRSA) is a type of bacteria that is resistant to certain antibiotics. ...

Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia

... faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus ... faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus anginosus grp. ...

More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL

... faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus ... faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus anginosus group ...

Cepheid Launches New GeneXpert(R) Tests in Europe for Simultaneous, Rapid Detection of Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus

... -- Methicillin Resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA) -- directly from blood cultures and soft tissue infection samples ... to numerous penicillin and cephalosporin antibiotics. "Staphylococcus aureus is a major cause of bloodstream infection, associated with substantial ...

FDA Accepts Wyeth's Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia

... faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus ... faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus anginosus group ...

McCaughey Urges Use of First NYS Hospital Infection Report

... Dr. McCaughey says the New York State infection report needs to be improved to include rates for methicillin resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. diff). More critically, the public should not be misled by risk adjustment infection, but should consider the ...

Great Basin Scientific, Inc. Raises $3.6 Million in Bridge Funding to Prepare for Launch of First Product

... As part of the preparation for an August clinical trial for its first test- a 50 minute diagnostic test for Methicillin resistant Staphylococcus aureus (MRSA) from a positive blood culture, Great Basin Scientific is leading several pre-clinical studies. The company conducted a successful feasibility ...

Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop

... for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus , including methicillin-resistant strains, and Cinryze(TM) (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in ...

Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures

... diagnostic tests for the rapid detection of healthcare-associated infections such as the potentially deadly Methicillin-Resistant Staphylococcus aureus (MRSA). (Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO ) Gayle Wittenberg, Program Manager at Siemens Corporate ...

Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)

... Ceftaroline is being developed as a therapeutic agent for the treatment of gram-positive pathogens including methicillin resistant staphylococcus aureus (MRSA), and multi-drug resistant streptococcus pneumoniae (MDRSP), as well as common gram-negative organisms. Ceftaroline is being studied as a ...

Rendell Administration Announces Health Research Grants From Tobacco Settlement Funds

... of these infections are caused by bacteria resistant to most, if not all, currently available drugs. Methicillin-resistant Staphylococcus aureus (MRSA) ranks among the most prevalent causes of infections in hospitals. It is easily transmitted within the hospital and is now found in the ...

ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients

... for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus , including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent ...

Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection

... age 13 in the United States, and results in one percent of all pediatric hospitalizations. Typically caused by the common bacteria Staphylococcus aureus , osteomyelitis usually appears as a fever with some discomfort in a child's leg or arm resulting from the bone infection. The average age of ...

FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)

... for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus , including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent ...

Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials

... DNA resulting in rapid "speed of kill". Phico envisages developing a fast-acting, easily applicable nasal gel which would combat both hospital S. aureus infection and hospital and community MRSA transmission and drug-resistance. According to Phico Therapeutics CEO and founder, Dr Heather ...

USD 12.5 m Funding for the Development of Intercell's Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)

... (start of Phase III expected in 2009), a Pseudomonas vaccine in Phase II, as well as a pandemic Influenza Vaccine Enhancement patch, a partnered S. aureus vaccine in Phase II and four products focused on infectious diseases in preclinical development. Intercell is listed on the Vienna stock ...

Novexel's NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections

... cephalosporin being developed as a therapeutic agent for the treatment of gram-positive pathogens including methicillin resistant staphylococcus aureus (MRSA), and multi-drug resistant streptococcus pneumoniae (MDRSP), as well as common gram-negative organisms. Ceftaroline is being studied as a ...

Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia

... oral streptogramin antibiotic that has potent in vitro activity against certain Gram positive bacteria including methicillin resistant Staphylococcus aureus (MRSA) as well as the important respiratory pathogens including penicillin, macrolide and quinolone resistant strains. The NXL103 Phase II study ...